{"favorite_id": 1718, "calc_type": "", "dosing": false, "full_title_en": "ATRIA Bleeding Risk Score", "short_title_en": "ATRIA Bleeding Risk", "medium_description_en": "Determines bleeding risk for patients on warfarin.", "short_description_en": "Bleeding risk from warfarin.", "before_use": "", "instructions_en": "", "purpose_en": ["Prognosis"], "disease_en": ["Arrhythmia", "Atrial Fibrillation", "Stroke/TIA"], "specialty_en": ["Cardiology", "Critical Care", "Emergency Medicine", "Family Practice", "Internal Medicine", "Neurology", "Primary Care"], "chief_complaint_en": ["Bleeding", "Palpitations"], "system_en": ["Cardiac", "Hematologic", "Neurologic"], "search_abbreviation_en": ["coumadin", "warfarin", "afib", "stroke risk"], "slug": "atria-bleeding-risk-score", "seo": {"meta_description_en": "The ATRIA bleeding score Determines bleeding risk in patients on warfarin for atrial fibrillation.", "keywords_en": "hemorrhage risk calculator, bleed risk warfarin, bleed risk coumadin, atria score, atria warfarin, atria calculator, atria risk, atrial fibrillation, bleeding score, atrial fibrillation bleeding risk, bleeding score"}, "content": {"how_to_use": {"use_case_en": "<ul> <li>The ATRIA risk scoring scheme, in combination with other risk stratification scores and physician gestalt, can be used to help guide the decision for warfarin therapy in patients in need of anticoagulation.</li> <li>The ATRIA risk scoring scheme may be used as one potential tool to stratify the risk of major hemorrhage in patients in whom warfarin anticoagulation is being considered.</li> </ul>", "pearls_pitfalls_en": "<p>The ATRIA study sought to develop a risk stratification score to predict warfarin-associated hemorrhage.</p> <ul> <li>Included patients from the Kaiser Permanente of Northern California hospital system with non-valvular, non-transient atrial fibrillation via their ICD-9 codes and then followed up for a period of six to seven years.</li> <li>Patients randomly divided into split-sample \u201cderivation\u201d and \u201cvalidation\u201d cohorts, in a 2:1 ratio, respectively.</li> <li>The study sought to identify risk factors for patients with major hemorrhage, defined as fatal, requiring transfusion of \u2265 2 units pRBCs, or hemorrhage into critical anatomic site (intracranial, retroperitoneal, etc).</li> <li>Five variables were derived after statistical analysis and then weighed based on degree of effect.</li> <li>Scoring system consisted of five criteria, each of which was worth 1, 2, or 3 points.</li> <li>Study used \u2264 3 points to define low probability group (&lt;1%) for major hemorrhage, 4 points for immediate (2.6%) and 5-10 points for high (5.8%).</li> </ul> <p><strong>Points to keep in mind:</strong></p> <ul> <li>Patients at risk for major hemorrhage, e.g. those with past intracranial bleeds, were likely already pre-excluded by clinicians and thus not included in the study</li> <li>The derivation and validation cohorts were taken from the same patient population with excellent follow-up</li> <li>Patients\u2019 INRs and potential for compliance were not taken into consideration</li> <li>The study did not compare the ATRIA score to the HAS-BLED score, which has been incorporated into European and Canadian atrial fibrillation guidelines</li> <li>Subsequent studies comparing the performance of the ATRIA and HAS-BLED bleeding risk-prediction scores showed that HAS-BLED had better prediction accuracy than ATRIA.</li> </ul>", "why_use_en": "<p>Considers major and minor risk of hemorrhage and bleeding in patients prior to beginning warfarin therapy</p> "}, "next_steps": {"advice_en": "", "management_en": "", "critical_actions_en": "<ul> <li>&lt;4 points - low risk</li> <li>4 points - intermediate risk</li> <li>&gt;4 points - high risk</li> </ul> <p>Patient specific risks and benefits of anticoagulation must be carefully weighed in all patients who are potential candidates for long-term warfarin therapy.</p> "}, "about": {"formula_en": "<p>Addition of the selected points:</p>\n<div class=\"table-responsive\">\n<table class=\"table table-bordered\">\n<tbody>\n<tr>\n<th>Risk Factor</th>\n<th>Point Value</th>\n</tr>\n<tr>\n<td>Anemia</td>\n<td>+3</td>\n</tr>\n<tr>\n<td>Severe Renal Disease/Dialysis</td>\n<td>+3</td>\n</tr>\n<tr>\n<td>Age &ge; 75</td>\n<td>+2</td>\n</tr>\n<tr>\n<td>Prior Hemorrhage</td>\n<td>+1</td>\n</tr>\n<tr>\n<td>Hypertension</td>\n<td>+1</td>\n</tr>\n</tbody>\n</table>\n</div>", "more_info_en": "<div class=\"table-responsive\"></div>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "http://content.onlinejacc.org/article.aspx?articleid=1146658", "text": "Fang MC, Go AS, Chang Y, et al. A New Risk Scheme to Predict Warfarin-Associated Hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401. doi:10.1016/j.jacc.2011.03.031."}], "Other References": [], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/22722228", "text": "Rold\u00e1n V, Mar\u00edn F, Fern\u00e1ndez H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a \"real-world\" population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143(1):179-184."}, {"href": "https://www.amjmed.com/article/S0002-9343(15)00926-2/fulltext", "text": "Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med. 2016;129(6):600-7."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "<p>Calvin Hwang, MD, is a clinical assistant professor in the department of orthopaedic surgery at the Stanford University School of Medicine. A native Californian, Dr. Hwang grew up in San Diego and attended Stanford University before venturing off to Case Western Reserve University School of Medicine, where he received his medical degree. He completed his residency at the Stanford/Kaiser Emergency Medicine program and fellowship in sports medicine at Stanford. He is currently a team physician for the Golden State Warriors, Stanford Football and Stanford Volleyball.</p>", "firstName": "Calvin", "img": "calvin-hwang.jpg", "lastName": "Hwang", "name": "Calvin Hwang, MD", "target": "calvin-hwang", "signedCOI": true, "hasDisclosure": []}]}, "creator": [{"id": 117, "name": "Dr. Daniel Singer", "qa_en": "", "approved": false, "priority": 0, "creator_info": {"about_en": "<p>Daniel Singer, MD, is a professor of medicine at Harvard Medical School and professor in the Department of Epidemiology at Harvard School of Public Health. He is also chief of the Clinical Epidemiology Unit in the General Medicine Division at Massachusetts General Hospital (MGH). Dr. Singer is internationally recognized for his research on prevention of stroke in atrial fibrillation (AF).</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-daniel-singer.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=Singer%20DE%5Bauth%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [{"id": 4, "order": 0, "link": "https://www.mdcalc.com/stroke-risk-atrial-fibrillation-practice-pearls", "text": "Practice Pearls: Atrial Fibrillation and Stroke Risk", "description": "Evidence syntheses and practical tips on management of atrial fibrillation", "CalculatorId": 1718, "createdAt": "2019-07-02T20:18:47.083Z", "updatedAt": "2022-03-21T20:13:50.672Z"}, {"id": 126, "order": 1, "link": "https://www.mdcalc.com/stroke-cme", "text": "MDCalc Stroke CME", "description": "Get up to 10 hours of stroke CME", "CalculatorId": 1718, "createdAt": "2022-03-21T20:13:50.699Z", "updatedAt": "2022-03-21T20:13:50.699Z"}], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Anemia", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Hemoglobin <13 g/dL (Male), <12 g/dL (Female)", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 3}], "name": "anemia"}, {"type": "toggle", "label_en": "Severe Renal Disease", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Glomerular filtration rate <30 mL/min or dialysis-dependent", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 3}], "name": "severe_renal_disease"}, {"type": "toggle", "label_en": "Age \u2265 75 years", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 2}], "name": "age_75"}, {"type": "toggle", "label_en": "Any Prior Hemorrhage Diagnosis", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Ex: GI bleed, intracranial hemorrhage", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "prior_hemorrhage_diagnosis"}, {"type": "toggle", "label_en": "Hypertension History", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "hypertension"}], "md5": "", "cmeVersion": "1718.1", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "related_calcs": [{"calcId": 1785, "short_title_en": "HEMORR<sub>2</sub>HAGES Score", "slug": "hemorr2hages-score-major-bleeding-risk"}, {"calcId": 807, "short_title_en": "HAS-BLED Score", "slug": "has-bled-score-major-bleeding-risk"}, {"calcId": 40, "short_title_en": "CHADS<sub>2</sub> Score", "slug": "chads2-score-atrial-fibrillation-stroke-risk"}]}